Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS (Nasdaq: SOPH) has announced that Kepler Uniklinikum, Austria's second largest hospital, has gone live with its SOPHiA DDM™ Platform. The hospital will use this platform to enhance its next-generation sequencing (NGS) testing and diagnostics specifically for blood cancers. Kepler Uniklinikum, housing 1,800 beds, aims to deepen its in-house NGS testing capabilities and expand services for patients with blood cancers and disorders. The SOPHiA DDM™ Platform provides nearly 100% reproducible results, supporting timely, cost-effective, and reliable sequencing data to aid in the rapid and accurate detection of genomic variants. This move is expected to benefit not only the local population but also provide valuable insights to other users of the platform globally.

SOPHiA GENETICS (Nasdaq: SOPH) has announced the launch of SOPHiA UNITY, a global consortium aimed at accelerating cancer research, drug development, and data-driven patient care. This initiative will unite leading healthcare institutions to harness large-scale, diverse data from multiple modalities, such as imaging, genomics, pathology, and clinical notes. The consortium will utilize the SOPHiA CarePath™ module on the SOPHiA DDM™ Platform to aggregate and analyze complex real-world data, offering valuable insights to members. Memorial Sloan Kettering Cancer Center is the first institution to join SOPHiA UNITY, with more members to be announced soon.

SOPHiA GENETICS (Nasdaq: SOPH) announced a collaboration with Microsoft and NVIDIA to launch a whole genome sequencing (WGS) analytical solution by end of 2024. The new WGS application aims to deliver fully analyzed genome insights within the same day, enhancing research, drug discovery, and clinical care. Leveraging Microsoft Azure and NVIDIA Parabricks, the solution will provide scalable and rapid genomic analysis, aiding researchers and clinicians in making data-driven decisions. The SOPHiA DDM™ platform integrates genomic data with other diagnostic modalities, aiming to support treatment planning and drug development efforts, particularly for cancer and rare genetic disorders.

SOPHiA GENETICS (Nasdaq: SOPH) announced that Instituto Mário Penna is now utilizing its SOPHiA DDM™ Platform. This Brazilian oncology center, located in Belo Horizonte, will use the platform to enhance its research and testing for blood cancers. The SOPHiA DDM™ Platform employs next-generation sequencing (NGS) to accurately target key variants from various sample types, aiding in timely and precise detection.

The Instituto Mário Penna, a major oncology service provider in Brazil, offers comprehensive cancer care including in-patient, out-patient, chemotherapy, radiation treatments, clinical laboratory analysis, and surgery. The integration of SOPHiA DDM™ aims to improve on-site diagnostic capabilities and support data-driven treatment decisions.

Blood cancers are the fifth most common type of cancer globally, and the institute's adoption of this AI-based technology reflects a commitment to advancing healthcare in Brazil.

SOPHiA GENETICS (Nasdaq: SOPH) has announced that the Klinikum Klagenfurt am Wörthersee, Austria's third-largest hospital, has implemented the SOPHiA DDM™ Platform. This technology aims to enhance the hospital's next-generation sequencing (NGS) testing and analytical capabilities for both solid tumors and blood cancers. It will assist in providing fast and accurate genomic analysis, aiding data-driven treatment decisions. The hospital's Institute for Laboratory Diagnostics and Microbiology (ILM) serves over half a million patients annually. The platform is expected to streamline data processing, offering reliable insights while conserving resources. This collaboration is set to improve precision medicine and molecular diagnostics at one of Austria's largest laboratories.

SOPHiA GENETICS, a cloud-native software company, reported Q1 2024 results with a 13% revenue growth to $15.8 million. Gross margins were 65.9% reported and 70.5% adjusted. Operating loss improved by 3% reported and 13% adjusted year-over-year. The company reaffirmed guidance: revenue growth of 25-30%, adjusted gross margin of 72.5-72.7%, and adjusted operating loss of $45-50 million. SOPHiA GENETICS signed debt financing for up to $50 million with Perceptive Advisors to accelerate growth. The company aims to onboard new customers and expand its Liquid Biopsy offering, MSK-ACCESS® powered with SOPHiA DDM™.

SOPHiA GENETICS, a cloud-native software company in data-driven medicine, will present at the 2024 RBC Capital Markets Global Healthcare Conference. Chief Financial Officer and Chief Operating Officer, Ross Muken, will speak on May 14, 2024, in New York City.